Humacyte, Inc. (NASDAQ:HUMA) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Humacyte has a “Moderate Buy” consensus rating from eight analysts, with six buys, one hold and one sell. The average 12-month price target is $4.96.
• Shares opened at $0.44 and were reported up 5.4%, while the company’s market capitalization stood at approximately $121 million. Humacyte recently missed quarterly expectations, reporting a $0.16 per-share loss and $0.41 million in revenue.
• Institutional investors own about 44.7% of Humacyte, and several hedge funds recently initiated positions. The company’s lead product, SYMVESS, received FDA approval in December 2024 for urgent treatment of extremity arterial injuries.

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $4.96.

Several research analysts recently weighed in on HUMA shares. Barclays raised shares of Humacyte to a "hold" rating in a research note on Wednesday, October 7th. HC Wainwright reaffirmed a "buy" rating on shares of Humacyte in a research note on Friday, October 16th. BTIG Research reiterated a "buy" rating and issued a $2.00 target price on shares of Humacyte in a report on Wednesday, August 12th. Benchmark reduced their price target on shares of Humacyte from $2.00 to $1.00 and set a "speculative buy" rating on the stock in a research report on Thursday, August 13th. Finally, Wall Street Zen lowered shares of Humacyte from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th.

Humacyte Trading Up 5.4%

NASDAQ:HUMA opened at $0.44 on Friday. Humacyte has a 1-year low of $0.34 and a 1-year high of $1.78. The business's 50-day moving average price is $0.54 and its two-hundred day moving average price is $0.74. The company has a current ratio of 6.21, a quick ratio of 5.74 and a debt-to-equity ratio of 2.07. The firm has a market capitalization of $120.95 million, a price-to-earnings ratio of -0.89 and a beta of 2.44.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The company had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.04 million. Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%. On average, equities analysts expect that Humacyte will post -0.40 earnings per share for the current year.

Institutional Trading of Humacyte

Hedge funds have recently added to or reduced their stakes in the business. HBK Investments L P bought a new stake in shares of Humacyte in the second quarter worth about $617,000. Miramontes Capital LLC bought a new position in shares of Humacyte during the 2nd quarter valued at about $85,000. Alyeska Investment Group L.P. bought a new position in shares of Humacyte during the 2nd quarter valued at about $4,700,000. Beacon Pointe Advisors LLC bought a new position in shares of Humacyte during the 2nd quarter valued at about $28,000. Finally, Stonepine Capital Management LLC acquired a new position in shares of Humacyte in the 2nd quarter valued at approximately $180,506. Institutional investors and hedge funds own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company's platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient.

Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.